Janux Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Janux Therapeutics

10/03/2024 21:01

* Janux Therapeutics Inc  JANX.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -39 cents.  The mean expectation of
four analysts for the quarter was for a loss of 39 cents per
share. Wall Street expected results to range from -47 cents
to -30 cents per share.
    * Revenue fell 13.5% to $2.46 million from a year ago;
analysts
expected $739.25 thousand. 
    * Janux Therapeutics Inc's reported EPS for the quarter was
a loss
of 25 cents​.
    * The company reported a quarterly loss of $11.76 million.
    * Janux Therapeutics Inc shares had risen by 278.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Janux
Therapeutics Inc is $30.00 

This summary was machine generated from LSEG data March 10 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.39          -0.25          Beat
 Sep. 30 2023      -0.47          -0.25          Beat
 Jun. 30 2023      -0.52          -0.42          Beat
 Mar. 31 2023      -0.49          -0.42          Beat